Alumis Inc. Common Stock (ALMS) Stock

Alumis Inc. Common Stock (ALMS) is a Healthcare stock trading at $23.37 (as of 2026-06-18), with a market capitalization of $2.51B and a trailing P/E of -13.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Alumis Inc. is a clinical-stage biopharmaceutical company developing medicines for autoimmune disorders. Its pipeline includes ESK-001, an allosteric TYK2 inhibitor for plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis, and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.

Valuation — source: SEC EDGAR (first-party)
Price	$23.37
Market Cap	$2.51B
P/E Ratio	-13.6
EV / EBITDA	-6.6
Price / Book	5.33
Price / Sales	359.44
DCF Value (model)	$-73.04
DCF Upside vs Price	-412.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$24.05M
Net Margin	-1011.7%
Return on Equity	-41.9%
Current Ratio	7.51
Revenue Growth (YoY)	34.9%
EPS Growth (YoY)	-103.4%
FCF Growth (YoY)	92.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	4.85 (safe)

Valuation vs Sector & Industry
Stock P/E	-13.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-164.7%
vs Industry	-178.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($157.97M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Martin Babler
Employees	168
Country	US
IPO Date	2021-02-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.